Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised Placebo-Controlled Single Blind Study to Investigate Single Ascending Doses of GNbAC1 in Multiple Sclerosis Patients Followed by Open-label Extension With Repeated Doses of GNbAC1

NCT01639300 is registered in ClinicalTrials.gov with GeNeuro Innovation SAS as lead sponsor.

NCT NCT01639300
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01639300 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised Placebo-Controlled Single Blind Study to Investigate Single Ascending Doses of GNbAC1 in Multiple Sclerosis Patients Followed by Open-label Extension With Repeated Doses of GNbAC1
Lead sponsor
GeNeuro Innovation SAS
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2012
Completion date
April 30, 2014
Enrollment
10 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis